Guggenheim Capital’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-49,194
| Closed | -$4.57M | – | 2210 |
|
|
2021
Q4 | $4.57M | Buy |
49,194
+4,313
| +10% | +$284K | 0.02% | 718 |
|
|
2021
Q3 | $2.67M | Buy |
44,881
+1,716
| +4% | +$101K | 0.02% | 905 |
|
|
2021
Q2 | $2.94M | Buy |
43,165
+2,176
| +5% | +$142K | 0.02% | 896 |
|
|
2021
Q1 | $2.84M | Buy |
40,989
+5,303
| +15% | +$408K | 0.02% | 855 |
|
|
2020
Q4 | $2.74M | Buy |
+35,686
| New | +$2.67M | 0.02% | 837 |
|
|
2016
Q1 | – | Sell |
-1,597
| Closed | -$30K | – | 3019 |
|
|
2015
Q4 | $30K | Buy |
+1,597
| New | +$32.6K | ﹤0.01% | 2903 |
|
|
2015
Q3 | – | Sell |
-2,095
| Closed | -$97K | – | 3044 |
|
|
2015
Q2 | $97K | Sell |
2,095
-115
| -5% | -$4.99K | ﹤0.01% | 2902 |
|
|
2015
Q1 | $97K | Buy |
2,210
+34
| +2% | +$1.58K | ﹤0.01% | 2861 |
|
|
2014
Q4 | $75K | Sell |
2,176
-74,493
| -97% | -$3.02M | ﹤0.01% | 2877 |
|
|
2014
Q3 | $3.21M | Buy |
76,669
+11,789
| +18% | +$526K | 0.01% | 1438 |
|
|
2014
Q2 | $3.8M | Sell |
64,880
-14,671
| -18% | -$924K | 0.01% | 1356 |
|
|
2014
Q1 | $5.01M | Buy |
79,551
+20,422
| +35% | +$1.35M | 0.01% | 1123 |
|
|
2013
Q4 | $3.46M | Sell |
59,129
-4,350
| -7% | -$227K | 0.01% | 1310 |
|
|
2013
Q3 | $3.35M | Buy |
63,479
+21,754
| +52% | +$1.46M | 0.01% | 1308 |
|
|
2013
Q2 | $3.21M | Buy |
+41,725
| New | +$3.41M | 0.01% | 1267 |
|
Guggenheim Capital's ARNA Position: Q1 2022 in Review
Guggenheim Capital sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 49,194 shares — an estimated $4.57M sold.
Guggenheim Capital first reported a position in ARNA in Q2 2013 and held it in 15 quarters. The position peaked at $5.01M in Q1 2014. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Guggenheim Capital reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Guggenheim Capital sold 49,194 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $4.57M.
- Guggenheim Capital first reported a position in Arena Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- Guggenheim Capital's Arena Pharmaceuticals Inc position peaked at $5.01M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Guggenheim Capital's 13F filing for Q1 2022, filed 16 May 2022.